|
Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June, 2026.
The company's revenue from operations increased by 26% YoY to Rs. 2,150 crore, while net profit was at Rs. 173 crore, up 12% YoY
Commenting on the results, Pranav Amin, managing director, Alembic Pharmaceuticals Limited, said, “We have started FY27 on a strong note, delivering broad-based growth across our businesses. Performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The US business delivered strong momentum, and the rest of the markets also recorded steady growth. We remain focused on strengthening our product portfolio, advancing our pipeline and driving sustainable long-term growth.”
The company India branded business delivered 7% YoY growth, reaching Rs. 642 crore in revenue for the quarter, while US formulation grew by 49% to Rs. 778 crore.
|